PedAM
Pediatric Disease Annotations & Medicines
| calcinosis | ||||
| Disease ID | 907 |
|---|---|
| Disease | calcinosis |
| Manually Symptom | (Waiting for update.) |
| Text Mined Symptom | (Waiting for update.) |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:2) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| snpId | pubmedId | geneId | geneSymbol | diseaseId | sourceId | sentence | score | Year | geneSymbol_dbSNP | CHROMOSOME | POS | REF | ALT |
| rs137853090 | 24038392 | 2591 | GALNT3 | umls:C0006663 | BeFree | From intriguing findings, T359K-GALNT3 was simulated with high contribution for disease susceptibility (tumor calcinosis) as compared to its partner variant T272K (Ichikawa et al. | 0.128444493 | 2013 | GALNT3 | 2 | 165761928 | G | T,A |
| rs137853091 | 24038392 | 2591 | GALNT3 | umls:C0006663 | BeFree | From intriguing findings, T359K-GALNT3 was simulated with high contribution for disease susceptibility (tumor calcinosis) as compared to its partner variant T272K (Ichikawa et al. | 0.128444493 | 2013 | GALNT3 | 2 | 165758862 | G | T |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
|---|
| (Waiting for update.) |
Chemical(Total Drugs:9) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C0006663 | cyclosporine | D016572 | 59865-13-3 | calcinosis | MESH:D002114 | marker/mechanism | 8080589 | ||
| C0006663 | calcitriol | D002117 | 32222-06-3 | calcinosis | MESH:D002114 | marker/mechanism | 16491297 | ||
| C0006663 | diltiazem | D004110 | 42399-41-7 | calcinosis | MESH:D002114 | therapeutic | 7488286 | ||
| C0006663 | foscarnet | D017245 | 4428-95-9 | calcinosis | MESH:D002114 | therapeutic | 24561004 | ||
| C0006663 | methotrexate | D008727 | 1959/5/2 | calcinosis | MESH:D002114 | marker/mechanism | 1053935 | ||
| C0006663 | mitomycin | D016685 | 1950/7/7 | calcinosis | MESH:D002114 | marker/mechanism | 1454338 | ||
| C0006663 | nicotine | D009538 | - | calcinosis | MESH:D002114 | marker/mechanism | 16378124 | ||
| C0006663 | cholecalciferol | D002762 | 67-97-0 | calcinosis | MESH:D002114 | marker/mechanism | 12803500 | ||
| C0006663 | vitamin e | D014810 | 1406-18-4 | calcinosis | MESH:D002114 | marker/mechanism | 11913585 | ||
FDA approved drug and dosage information(Total Drugs:1) | ||||||||
|---|---|---|---|---|---|---|---|---|
| DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
| MESH:D002114 | calcijex | calcitriol | 0.001MG/ML Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons | INJECTABLE;INJECTION | Discontinued | None | Yes | No |
FDA labeling changes(Total Drugs:1) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
| MESH:D002114 | 11/16/2001 | calcijex | calcitriol | Management of hypocalcemia in patients undergoing chronic renal dialysis | The safety and effectiveness of calcitriol was examined in a double-blind placebo-controlled trial of 35 pediatric patients (13-18 years of age) with end-stage renal disease and on dialysis. The primary efficacy endpoint favored the calcitriol-treated versus the placebo-treated patients Transient hypercalcemia was seen in 1 of 16 calcitriol-treated patients; 6 of 16 (38%) calcitriol-treated patients and 2 of 19 (11%) placebo-treated patients had Ca x P >75 | Labeling | B | - | - | - | Abbott | 02/16/2001 | FALSE' |